AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21860242 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 0
Study 19074594 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (angiotensin II type 1 receptor antagonist)
Number of subjects: 0
Study 19074594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17002566 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral neck EI to TSM ratio
Number of subjects: 700
Study 15119520 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient strategy using low‐molecular‐weight heparin, dalteparin, administered subcutaneously once daily, adjusted for body weight.
Number of subjects: 131
Study 15119520 — intervention group
Group type: COMPARATOR
Intervention: Inpatient strategy using low‐molecular‐weight heparin, dalteparin, administered subcutaneously once daily, adjusted for body weight.
Number of subjects: 131
Study 10665615 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 600 mg/wk
Number of subjects: 56
Study 9032651 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacarpophalangeal pattern profile analysis in affected individuals
Number of subjects: 0
Study 9032651 — intervention group
Group type: COMPARATOR
Intervention: Comparison with unaffected individuals from the same family
Number of subjects: 0
Study 9032651 — intervention group
Group type: COMPARATOR
Intervention: Comparison with people with a different genetic background
Number of subjects: 0
Study 7984574 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies OKT-4 and OKT-8 used in tuberculous patients
Number of subjects: 174
Study 7984574 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects of different age
Number of subjects: 174
Study 3549800 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minoxidil solution
Number of subjects: 56
Study 3549800 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% minoxidil solution
Number of subjects: 56
Study 3549800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 30571562 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide
Number of subjects: 11066
Study 30571562 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of angiotensin-converting enzyme inhibitor-based therapy
Number of subjects: 11066
Study 30571562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11066
Study 29587729 — intervention group
Group type: EXPERIMENTAL
Intervention: Axium spinal cord stimulation (SCS) of the dorsal root ganglion (DRG)
Number of subjects: 78
Study 29587729 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management (CMM)
Number of subjects: 78
Study 26740197 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal prolapse repair with midurethral sling (MUS)
Number of subjects: 231
Study 26740197 — intervention group
Group type: COMPARATOR
Intervention: Vaginal prolapse repair without midurethral sling (MUS)
Number of subjects: 231
Study 25251676 — intervention group
Group type: EXPERIMENTAL
Intervention: ADF-L (lunch)
Number of subjects: 74
Study 25251676 — intervention group
Group type: EXPERIMENTAL
Intervention: ADF-D (dinner)
Number of subjects: 74
Study 25251676 — intervention group
Group type: EXPERIMENTAL
Intervention: ADF-SM (small meals)
Number of subjects: 74
Study 22385437 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency lesioning of the sensory branches of the obturator and femoral nerves
Number of subjects: 18
Study 21164045 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin group (10 participants) ingested 8 g of curcuminoids (C(3)‐Complex) with 16 oz of bottled water.
Number of subjects: 15
Study 21164045 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 participants) did not take curcumin.
Number of subjects: 15
Study 18066139 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-source tryptophan (deoiled gourd seed) in combination with carbohydrate
Number of subjects: 7
Study 18066139 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate alone
Number of subjects: 7
Study 15231439 — intervention group
Group type: EXPERIMENTAL
Intervention: Abused/neglected patients
Number of subjects: 51
Study 15231439 — intervention group
Group type: EXPERIMENTAL
Intervention: Neglect
Number of subjects: 51
Study 15231439 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 51
Study 11295690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole technetium 99m sestamibi SPECT imaging
Number of subjects: 203
Study 11295690 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest thallium imaging
Number of subjects: 203
Study 11295690 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-dose warfarin sodium and aspirin)
Number of subjects: 203
Study 9243262 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam
Number of subjects: 242
Study 9243262 — intervention group
Group type: COMPARATOR
Intervention: clindamycin
Number of subjects: 242
Study 8500309 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimization method of Taves
Number of subjects: 0
Study 8500309 — intervention group
Group type: COMPARATOR
Intervention: Stratified assignment method
Number of subjects: 0
Study 3326113 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 3.75 mg
Number of subjects: 6
Study 3326113 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 6
Study 3326113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29463098 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 30
Study 29463098 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 30
Study 27064030 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone (DRP)‐containing COCs, combined with metformin (1.5 g/d) and lifestyle modifications
Number of subjects: 99
Study 27064030 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate (CPA)‐containing COCs, combined with metformin (1.5 g/d) and lifestyle modifications
Number of subjects: 99
Study 24637997 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with chemotherapy (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks)
Number of subjects: 361
Study 24637997 — intervention group
Group type: COMPARATOR
Intervention: Single-agent chemotherapy alone
Number of subjects: 361
Study 24637997 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with chemotherapy
Number of subjects: 361
Study 24637997 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 361
Study 20521348 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (four cycles of carboplatin and paclitaxel)
Number of subjects: 250
Study 20521348 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of mucin
Number of subjects: 250
Study 20521348 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of p53
Number of subjects: 250
Study 20521348 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 250
Study 20521348 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger tumor volume
Number of subjects: 250
Study 17517949 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrimethamine (50 mg/day) plus sulfadiazine (4 g/day) and folinic acid (25 mg/day)
Number of subjects: 3
Study 17517949 — intervention group
Group type: COMPARATOR
Intervention: trimethoprim (10 mg/kg/day) plus sulfamethoxazole (50 mg/kg/day) (TMP‐SMX)
Number of subjects: 3
Study 16826020 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (60-75% of maximal heart rate), 5 days/week for 12 months
Number of subjects: 173
Study 16826020 — intervention group
Group type: COMPARATOR
Intervention: Stretching sessions once a week
Number of subjects: 173
Study 12792513 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (folic acid 5 mg/day; vitamin B(6) 50 mg/day; vitamin B(12) 400 microg)
Number of subjects: 56
Study 12792513 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 56
Study 10676599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Optison® (FS069) at 0.5 ml
Number of subjects: 191
Study 10676599 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Optison® (FS069) at higher doses (0.2, 3.0, and 5.0 ml)
Number of subjects: 191
Study 10676599 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse event rate with Optison®
Number of subjects: 191
Study 8800113 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of high dose furosemide (mean daily dosage 690 mg, range 250 to 2,000)
Number of subjects: 20
Study 8800113 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of high dose furosemide (equal dosage to infusion)
Number of subjects: 20
Study 8800113 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of high dose furosemide
Number of subjects: 20
Study 8800113 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of high dose furosemide
Number of subjects: 20
Study 1624171 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycine amino acid solution (23% glycine nitrogen)
Number of subjects: 14
Study 1624171 — intervention group
Group type: COMPARATOR
Intervention: Low glycine amino acid solution (4% glycine nitrogen)
Number of subjects: 14
Study 1624171 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycine amino acid solution (25% glycine nitrogen)
Number of subjects: 14
Study 1624171 — intervention group
Group type: COMPARATOR
Intervention: Low glycine amino acid solution (8% glycine nitrogen)
Number of subjects: 14
Study 6377884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate at 35.6 degrees C
Number of subjects: 17
Study 6377884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate at 36.7 degrees C
Number of subjects: 17
Study 6377884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate at 37.8 degrees C
Number of subjects: 17
Study 6377884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate cooler than isothermic levels
Number of subjects: 17
Study 6377884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate warmer than isothermic levels
Number of subjects: 17
Study 30654297 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab + CC-486
Number of subjects: 100
Study 30654297 — intervention group
Group type: COMPARATOR
Intervention: pembrolizumab + placebo
Number of subjects: 100
Study 28560591 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-level factors (younger age)
Number of subjects: 2968
Study 28560591 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial-level factors (living with only one parent or another person while growing up)
Number of subjects: 2968
Study 28560591 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender (among foreign-born youth)
Number of subjects: 2968
Study 28560591 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental education level (among Swedish-born youth)
Number of subjects: 2968
Study 28560591 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use
Number of subjects: 2968
Study 26746436 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual microscopy adaptive tutorials (VMATs)
Number of subjects: 0
Study 26746436 — intervention group
Group type: COMPARATOR
Intervention: Existing resources (e-textbooks and online atlases)
Number of subjects: 0
Study 24717919 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus cetuximab
Number of subjects: 257
Study 24717919 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 257
Study 22394464 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised management based on international guidelines
Number of subjects: 80
Study 22394464 — intervention group
Group type: COMPARATOR
Intervention: Usual heart failure management by general practitioners
Number of subjects: 80
Study 19158225 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA oil (7.5 g/d, 3 g DHA/d)
Number of subjects: 34
Study 17192287 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet transplantation
Number of subjects: 15
Study 17192287 — intervention group
Group type: COMPARATOR
Intervention: Type 1 diabetes group
Number of subjects: 15
Study 12607378 — intervention group
Group type: EXPERIMENTAL
Intervention: Web based IT solutions for studies and registers
Number of subjects: 0
Study 12607378 — intervention group
Group type: EXPERIMENTAL
Intervention: Central database for randomization and stratification
Number of subjects: 0
Study 12607378 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient direct data reporting into the database
Number of subjects: 0
Study 12607378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of web based IT solutions
Number of subjects: 0
Study 10979879 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (200 mg/wk)
Number of subjects: 54
Study 10979879 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (three times weekly)
Number of subjects: 54
Study 10979879 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 54
Study 10979879 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 54
Study 8780431 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol (18 g/day)
Number of subjects: 13
Study 8780431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 1467134 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg BAY u 3405
Number of subjects: 0
Study 1467134 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg BAY u 3405
Number of subjects: 0
Study 1467134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6382673 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg
Number of subjects: 10
Study 6382673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30614769 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS group (n=100)
Number of subjects: 200
Study 30614769 — intervention group
Group type: COMPARATOR
Intervention: CON group (n=100)
Number of subjects: 200
Study 27814306 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training with Thera-Band for 30 minutes, five times a week for four weeks
Number of subjects: 30
Study 27814306 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy for 30 minutes followed by treadmill training only for 30 minutes
Number of subjects: 30
Study 25294865 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide 7.5 mg
Number of subjects: 60
Study 25294865 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg
Number of subjects: 60
Study 25294865 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide 3.75 mg
Number of subjects: 60
Study 25294865 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 60
Study 23757126 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 10-week high-intermediate intensity aerobic exercise program (75-85% HRR)
Number of subjects: 62
Study 23757126 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - no intervention
Number of subjects: 62
Study 21501811 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV education intervention designed in the United States and adapted for Swaziland
Number of subjects: 135
Study 21501811 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 135
Study 18685605 — intervention group
Group type: EXPERIMENTAL
Intervention: Sour tea (Hibiscus sabdariffa)
Number of subjects: 60
Study 18685605 — intervention group
Group type: COMPARATOR
Intervention: Black tea infusion
Number of subjects: 60
Study 16706758 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen fat
Number of subjects: 10
Study 16706758 — intervention group
Group type: COMPARATOR
Intervention: Fresh fat
Number of subjects: 10
Study 16500347 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification with DMSO using rapid cooling
Number of subjects: 0
Study 16500347 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification with DMSO using slow cooling (long exposure)
Number of subjects: 0
Study 16500347 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification with DMSO using slow cooling (short exposure)
Number of subjects: 0
Study 16500347 — intervention group
Group type: COMPARATOR
Intervention: Vitrification without DMSO using slow cooling
Number of subjects: 0
Study 16500347 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification with long-term contact of oocytes with DMSO
Number of subjects: 0
Study 16500347 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification with short-term contact of oocytes with DMSO at room temperature
Number of subjects: 0
Study 10787075 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (low dose intravenous epirubicin 20 mg/m2 and mitomycin 5 mg monthly for seven courses starting 5 to 6 weeks after surgery)
Number of subjects: 49
Study 10787075 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant treatment)
Number of subjects: 49
Study 10787075 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 49
Study 8857631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (i.v.)
Number of subjects: 0
Study 8857631 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 1513962 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified PNF techniques (PCP, 3-PIECP, 3-PIFCP)
Number of subjects: 120
Study 1513962 — intervention group
Group type: COMPARATOR
Intervention: Passive stretch technique (P)
Number of subjects: 120
Study 1513962 — intervention group
Group type: COMPARATOR
Intervention: Cold application
Number of subjects: 120
Study 6827877 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group using a test order form that included actual test prices
Number of subjects: 59
Study 6827877 — intervention group
Group type: COMPARATOR
Intervention: Control group using a test order form without actual prices
Number of subjects: 59
Study 30299473 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (simvastatin)
Number of subjects: 64
Study 30299473 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated high blood cholesterol)
Number of subjects: 64
Study 29730268 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral thoracic paravertebral block at T8 with an infusion of 0.2% ropivacaine
Number of subjects: 53
Study 29730268 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia at T7/8 with an infusion of 0.125% bupivacaine with hydromorphone 6 μg/mL
Number of subjects: 53
Study 26583966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume training (2 sets of 5 repetitions, twice a week)
Number of subjects: 47
Study 26583966 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate volume training (4 sets of 5 repetitions, twice a week)
Number of subjects: 47
Study 26583966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 47
Study 24822261 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-supported interprofessional education (IPE)
Number of subjects: 0
Study 24822261 — intervention group
Group type: COMPARATOR
Intervention: Pretest-posttest composite attitude toward teamwork scores
Number of subjects: 0
Study 22438360 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session RF ablation (group 1)
Number of subjects: 30
Study 22438360 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session RF ablation (group 2)
Number of subjects: 30
Study 22438360 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group 1 and group 2
Number of subjects: 30
Study 20657772 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotionally positive opponents
Number of subjects: 0
Study 20657772 — intervention group
Group type: COMPARATOR
Intervention: Threatening face information
Number of subjects: 0
Study 18366642 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI > or = 30 kg/m2)
Number of subjects: 6188
Study 18366642 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 6188
Study 18366642 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (BP > or = 140/90 mmHg and/or treatment)
Number of subjects: 6188
Study 18366642 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidemia (high LDL-cholesterol and/or low HDL-cholesterol and/or high triglyceride levels)
Number of subjects: 6188
Study 18366642 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (fasting plasma glucose > or = 7 mmol/l and/or treatment)
Number of subjects: 6188
Study 15981865 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic nose intervention for detecting changes in body odor due to renal dysfunction
Number of subjects: 0
Study 15981865 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 0
Study 12677354 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (acute tryptophan depletion via an amino acid drink lacking tryptophan)
Number of subjects: 0
Study 12677354 — intervention group
Group type: COMPARATOR
Intervention: Control mixture (balanced mixture of amino acids)
Number of subjects: 0
Study 10573236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization to cat
Number of subjects: 11215
Study 10573236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization to house dust mite
Number of subjects: 11215
Study 10573236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization to timothy grass
Number of subjects: 11215
Study 10573236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization to Cladosporium
Number of subjects: 11215
Study 9592303 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1,000 mg twice daily for 1 week
Number of subjects: 141
Study 9592303 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1,000 mg twice daily for 2 weeks
Number of subjects: 141
Study 9592303 — intervention group
Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate 240 mg twice daily, amoxicillin 1,000 mg twice daily, metronidazole 400 mg twice daily for 2 weeks
Number of subjects: 141
Study 1872348 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple choice response format (oral and written)
Number of subjects: 1078